Lineage Cell Therapeutics Q2 2025: OpRegen Progress and Diversification Strategy

Lineage Cell Therapeutics reported Q2 2025 earnings, with CEO Brian M. Culley highlighting sustained progress for OpRegen, a treatment for dry age-related macular degeneration. He noted that OpRegen's anatomical and functional benefits have lasted for 3 years, and that patients with full OpRegen coverage gained significant vision. The company also has a $42.3M cash position, indicating a strong financial position to support its expanded diversification strategy.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) reported its second quarter 2025 financial and operating results, with CEO Brian M. Culley highlighting sustained progress for OpRegen, a treatment for dry age-related macular degeneration (AMD). The company's quarterly earnings were bolstered by a strong cash position, indicating a robust financial foundation to support its expanded diversification strategy.

OpRegen, a retinal pigment epithelial (RPE) cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, has shown promising long-term clinical outcomes. According to Culley, among patients who received extensive one-time coverage of OpRegen RPE cells across the area of atrophy, anatomical and functional benefits have lasted for at least three years. This finding is significant as it challenges the long-held view that geographic atrophy (GA) is an irreversible condition. The company expects to present 36-month results from a Phase 1/2a clinical study of OpRegen at Clinical Trials at the Summit (CTS) 2025, scheduled for June 20-21, 2025.

Lineage's financial position remains strong, with a $42.3M cash position at the end of Q2 2025. This substantial liquidity supports the company's ongoing research and development efforts, as well as its plans to diversify its product pipeline. The company continues to make progress in its neuroscience-focused pipeline, which includes additional cell therapies for spinal cord injuries, auditory neuropathy, vision loss, and hypoimmune induced pluripotent stem cell lines.

In addition to its financial results, Lineage also reported the first chronic patient treated in a new clinical study of OPC1 in patients with subacute and chronic spinal cord injury. The company hosted its 3rd Annual SCI Investor Symposium, further demonstrating its commitment to advancing cell therapies for serious neurological conditions.

Overall, Lineage's Q2 2025 earnings reflect the company's strong financial position and continued progress in its cell therapy pipeline. The presentation of 36-month results for OpRegen at CTS 2025 is expected to provide further insights into the potential of this treatment for patients with GA secondary to AMD.

References:
[1] https://www.businesswire.com/news/home/20250512395886/en/RG6501-OpRegen-Phase-12a-Clinical-Study-36-Month-Results-to-Be-Featured-at-Clinical-Trials-at-the-Summit-2025
[2] https://www.nasdaq.com/press-release/lineage-cell-therapeutics-reports-second-quarter-2025-financial-results-and-provides